Viracta Therapeutics (VIRX) Competitors $0.0098 0.00 (0.00%) As of 07/17/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIRX vs. PTN, AWH, ALZN, CDT, PCSA, APVO, PWUP, SCNI, VCNX, and PTIXShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Palatin Technologies (PTN), Aspira Women's Health (AWH), Alzamend Neuro (ALZN), Conduit Pharmaceuticals (CDT), Heatwurx (PCSA), Aptevo Therapeutics (APVO), PowerUp Acquisition (PWUP), Scinai Immunotherapeutics (SCNI), Vaccinex (VCNX), and Atrinsic (PTIX). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Its Competitors Palatin Technologies Aspira Women's Health Alzamend Neuro Conduit Pharmaceuticals Heatwurx Aptevo Therapeutics PowerUp Acquisition Scinai Immunotherapeutics Vaccinex Atrinsic Viracta Therapeutics (NASDAQ:VIRX) and Palatin Technologies (NYSE:PTN) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Does the media prefer VIRX or PTN? In the previous week, Viracta Therapeutics' average media sentiment score of 0.00 equaled Palatin Technologies'average media sentiment score. Company Overall Sentiment Viracta Therapeutics Neutral Palatin Technologies Neutral Which has preferable earnings and valuation, VIRX or PTN? Palatin Technologies has higher revenue and earnings than Viracta Therapeutics. Palatin Technologies is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01Palatin Technologies$350K6.99-$40.31M-$1.55-0.06 Which has more risk & volatility, VIRX or PTN? Viracta Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Do analysts prefer VIRX or PTN? Viracta Therapeutics presently has a consensus target price of $1.75, suggesting a potential upside of 17,793.66%. Given Viracta Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Viracta Therapeutics is more favorable than Palatin Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Palatin Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is VIRX or PTN more profitable? Palatin Technologies' return on equity of 0.00% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viracta TherapeuticsN/A -1,899.61% -114.21% Palatin Technologies N/A N/A N/A Do insiders & institutionals hold more shares of VIRX or PTN? 31.4% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Palatin Technologies shares are held by institutional investors. 10.7% of Viracta Therapeutics shares are held by company insiders. Comparatively, 7.1% of Palatin Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryViracta Therapeutics beats Palatin Technologies on 8 of the 12 factors compared between the two stocks. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$389K$817.60M$5.55B$9.40BDividend YieldN/A4.84%3.75%4.03%P/E Ratio-0.011.4128.0119.82Price / SalesN/A27.13432.8198.20Price / CashN/A19.5636.1658.27Price / Book0.036.878.125.65Net Income-$51.06M-$4.17M$3.25B$257.91M7 Day PerformanceN/A-0.12%1.68%3.38%1 Month PerformanceN/A1.85%7.30%11.11%1 Year PerformanceN/A4.45%32.89%18.99% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics2.0262 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120PTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's HealthN/A$0.08-12.5%$5.50+6,607.3%-94.5%$2.44M$9.18M-0.07110High Trading VolumeALZNAlzamend Neuro2.1818 of 5 stars$2.88-2.0%$180.00+6,150.0%-90.4%$2.35MN/A0.004CDTConduit Pharmaceuticals0.3923 of 5 stars$2.42-17.1%N/A-99.5%$2.33MN/A0.003Gap DownHigh Trading VolumePCSAHeatwurx2.2249 of 5 stars$0.19-0.5%$2.00+932.0%-87.0%$2.32MN/A-0.0620APVOAptevo Therapeutics2.3911 of 5 stars$2.90-4.6%$219,040.00+7,553,003.4%-100.0%$2.30M$3.11M0.0050Gap DownPWUPPowerUp AcquisitionN/A$0.29+2.4%N/A-96.8%$2.27MN/A0.00N/AHigh Trading VolumeSCNIScinai ImmunotherapeuticsN/A$2.15-2.3%N/A-52.2%$2.20M$660K-0.2220VCNXVaccinex0.8361 of 5 stars$0.80+14.4%N/A-88.2%$2.08M$388K-0.0240PTIXAtrinsic0.4305 of 5 stars$3.39-2.0%N/A-67.6%$2.04MN/A-0.262 Related Companies and Tools Related Companies PTN Alternatives AWH Alternatives ALZN Alternatives CDT Alternatives PCSA Alternatives APVO Alternatives PWUP Alternatives SCNI Alternatives VCNX Alternatives PTIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRX Stock Alerts